Sina Bavari
Corporate Officer/Principal bei TONIX PHARMACEUTICALS HOLDING CORP.
Profil
Sina Bavari is the founder of Healion Bio, Inc. He currently works as the EVP-Infectious Disease Research & Development at Tonix Pharmaceuticals Holding Corp.
Previously, he worked as the Chief Scientific Officer at the U.S.
Army Medical Research Institute for Infectious Diseases.
Bavari holds a graduate degree from the University of Southern California and a doctorate from the University of Nebraska Medical Center.
Aktive Positionen von Sina Bavari
| Unternehmen | Position | Beginn |
|---|---|---|
| TONIX PHARMACEUTICALS HOLDING CORP. | Corporate Officer/Principal | 25.07.2022 |
Healion Bio, Inc.
 Healion Bio, Inc. BiotechnologyHealth Technology Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million. | Gründer | - |
Ehemalige bekannte Positionen von Sina Bavari
| Unternehmen | Position | Ende |
|---|---|---|
| U.S. Army Medical Research Institute for Infectious Diseases | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Sina Bavari
| University of Southern California | Graduate Degree |
| University of Nebraska Medical Center | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TONIX PHARMACEUTICALS HOLDING CORP. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Healion Bio, Inc.
Healion Bio, Inc. BiotechnologyHealth Technology Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million. | Health Technology |
